Skye Bioscience, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Quiver, QurAlis To Combine Tech Platfor

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

By 2040, over half a billion people could be taking GLP-1 agonists or other weight loss medicines, according to McKinsey. A market that barely existed prior to 2021 could be worth over $100bn by 2030

Amongst a crowded research space, Skye Bioscience, Inc. aims to differentiate itself with a longer-term approach to combatting obesity. Its lead asset, nimacimab, functions as a negative allosteric